AnalystsEvan David Seigerman
Evan David Seigerman's Stock Forecasts

Analyst Ranking
Top 25%
#1252 out of 5177 analysts
Average Return
+7.18%
Win Rate
48%24 out of 50
Risk vs Reward
Poor
Good

Evan David Seigerman's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Candel Therapeutics IncCADL
+568.75%$1.60$10.70
2023-05-14 -
2024-05-14
Buy
Morphic Holding IncMORF
+147.53%$22.49$55.67
2023-09-27 -
2024-07-09
Buy
Eli Lilly & CoLLY
+81.93%$306.82$558.19
2022-09-05 -
2023-09-05
Buy
Acadia Pharmaceuticals IncACAD
+76.44%$14.73$25.99
2025-04-16 -
2026-01-16
Buy
Merus NvMRUS
+63.22%$55.14$90.00
2025-05-22 -
2025-12-29
Buy

Evan David Seigerman's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Merck & Co IncMRK
5Buy$130.00+19.45%Upgrades
a month ago
Regeneron Pharmaceuticals IncREGN
9Buy$850.00+15.96%Maintains
a month ago
Amgen IncAMGN
5Buy$372.00+12.59%Maintains
a month ago
Novo Nordisk A SNVO
8Hold$46.00-26.20%Maintains
2 months ago
Replimune Group IncREPL
5Hold$11.00+56.25%Upgrades
2 months ago
Abbvie IncABBV
8Buy$240.00+11.97%Maintains
4 months ago
Neurogene IncNGNE
2Buy$26.00+48.15%Maintains
7 months ago
Merus NvMRUS
1Buy$110.00+22.22%Maintains
8 months ago
Acadia Pharmaceuticals IncACAD
2Buy$28.00+7.73%Maintains
8 months ago
Arvinas IncARVN
1Buy$10.00-18.03%Maintains
8 months ago
Disc Medicine IncIRON
1Buy$112.00N/AMaintains
a year ago
Morphic Holding IncMORF
3Hold$57.00N/ADowngrades
2 years ago
Structure Therapeutics IncGPCR
2Buy$100.00N/AMaintains
2 years ago
Pfizer IncPFE
4Buy$36.00N/AReiterates
2 years ago
Mirati Therapeutics IncMRTX
4Hold$72.00N/AMaintains
2 years ago
Candel Therapeutics IncCADL
1Buy$3.00N/AMaintains
3 years ago
Eli Lilly & CoLLY
1Buy$396.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.